Iranian
Biomedical Journal
Volume 28, Issue 4 (7-2024)
IBJ 2024, 28(4): 206-213 |
Back to browse issues page
Ethics code: IR.PII.REC.1401.038
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jahani M M, Mashayekhi P, Omrani M D, Khosravi A, Dehghanifard A, Azad Manjiri S, et al . Assessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for EGFR Mutation Detection in NSCLC. IBJ 2024; 28 (4) :206-213
URL: http://ibj.pasteur.ac.ir/article-1-4289-en.html
URL: http://ibj.pasteur.ac.ir/article-1-4289-en.html
Mohammad Mehdi Jahani 
, Parisa Mashayekhi * , Mir Davood Omrani , Adnan Khosravi , Ali Dehghanifard , Sanam Azad Manjiri , Mahyar Zahraie , Maryam Mabani , Sharareh Seifi , Babak Salimi , Parsa Rostami
, Parisa Mashayekhi * , Mir Davood Omrani , Adnan Khosravi , Ali Dehghanifard , Sanam Azad Manjiri , Mahyar Zahraie , Maryam Mabani , Sharareh Seifi , Babak Salimi , Parsa Rostami
Abstract:
Background: Early and minimally invasive detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients is a promising tool to select patients for targeted therapy in order to improve their prognosis. This study aimed to identify a sensitive, cost-effective, and easily accessible noninvasive method for detecting the EGFR-targetable mutations in the plasma exosomal DNA (exoDNA)+ of patients with NSCLC.
Methods: This retrospective observational study was conducted over 10 months, from December 2022 to October 2023, at Masih Daneshvari Hospital in Tehran, Iran. A total of 30 patients with stage II-IV NSCLC and targetable mutation in the EGFR gene were included in the study. Nested PCR and Sanger sequencing were used to evaluate EGFR mutations in the DNA extracted from circulating exosomes.
Results: The study found a sensitivity of 76.6% for EGFR mutation detection on exoDNA compared to tissue results. No significant impact was observed based on tumor staging, histology, mutation type, smoking status, gender, or age.
Conclusion: Therapeutically targetable driver mutations in the EGFR gene can be accurately detected using nested PCR followed by direct sequencing of plasma exoDNA from patients with NSCLC. This approach facilitates timely and more personalized treatment for NSCLC patients, ultimately improving patient prognosis. Additionally, this method reduces the reliance on invasive tissue biopsies and their associated complications.
Methods: This retrospective observational study was conducted over 10 months, from December 2022 to October 2023, at Masih Daneshvari Hospital in Tehran, Iran. A total of 30 patients with stage II-IV NSCLC and targetable mutation in the EGFR gene were included in the study. Nested PCR and Sanger sequencing were used to evaluate EGFR mutations in the DNA extracted from circulating exosomes.
Results: The study found a sensitivity of 76.6% for EGFR mutation detection on exoDNA compared to tissue results. No significant impact was observed based on tumor staging, histology, mutation type, smoking status, gender, or age.
Conclusion: Therapeutically targetable driver mutations in the EGFR gene can be accurately detected using nested PCR followed by direct sequencing of plasma exoDNA from patients with NSCLC. This approach facilitates timely and more personalized treatment for NSCLC patients, ultimately improving patient prognosis. Additionally, this method reduces the reliance on invasive tissue biopsies and their associated complications.
Type of Study: Full Length/Original Article |
Subject:
Molecular Genetics & Genomics
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. [DOI:10.3322/caac.21551]
2. Gadgeel SM. Personalized therapy of non-small cell lung cancer (NSCLC). Adv Exp Med Biol. 2016; 890:203-22. [DOI:10.1007/978-3-319-24932-2_11]
3. Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022; 15(1):173. [DOI:10.1186/s13045-022-01391-4]
4. Hirsch FR, Suda K, Wiens J, Bunn PA. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016; 388(10048):1012-24. [DOI:10.1016/S0140-6736(16)31473-8]
5. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. [DOI:10.1016/S1470-2045(11)70184-X]
6. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016; 6(5):479-91. [DOI:10.1158/2159-8290.CD-15-1483]
7. Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014; 24(6):766-9. [DOI:10.1038/cr.2014.44]
8. Calabuig-Farinas S, Jantus-Lewintre E, Herreros-Pomares A, Camps C. Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? Trans Lung Cancer Res. 2016; 5(5):466-82. [DOI:10.21037/tlcr.2016.10.02]
9. Uyar R, Özçelikay G, Kaya Sİ, Nergis SB, Beşbinar Ö, Ünal MA, et al. Early cancer detection based on exosome biosensors in biological samples. Sens Actuators B Chem. 2024; 400:134886. [DOI:10.1016/j.snb.2023.134886]
10. Kahlert C. Liquid biopsy: is there an advantage to analyzing circulating exosomal DNA compared to cfDNA or are they the same? Cancer Res. 2019; 79(10):2462-5. [DOI:10.1158/0008-5472.CAN-19-0019]
11. Yu W, Hurley J, Roberts D, Chakrabortty S, Enderle D, Noerholm M, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021; 32(4):466-77. [DOI:10.1016/j.annonc.2021.01.074]
12. Bordi P, Del Re M, Danesi R, Tiseo M. Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2015; 4(5):584-97.
13. Wang X, Liu Y, Meng Z, Wu Y, Wang S, Jin G, et al. Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer. Ann Transl Med. 2021; 9(8):635. [DOI:10.21037/atm-20-7155]
14. Kim HR, Lee SY, Hyun DS, Lee MK, Lee HK, Choi CM, et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res. 2013; 32:1-8. [DOI:10.1186/1756-9966-32-50]
15. Zaini J, Syahruddin E, Yunus M, Andarini SL, Hudoyo A, Masykura N, et al. Evaluation of PCR‐HRM, RFLP, and direct sequencing as simple and cost‐effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients. Cancer Rep (Hoboken). 2019; 2(4):e1159. [DOI:10.1002/cnr2.1159]
16. Castellanos-Rizaldos E, Zhang X, Tadigotla VR, Grimm DG, Karlovich C, Raez LE, et al. Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients. Oncotarget. 2019;10(30):2911-20. [DOI:10.18632/oncotarget.26885]
17. Steendam CM, Atmodimedjo P, de Jonge E, Paats MS, van der Leest C, Oomen-de Hoop E, et al. Plasma cell-free DNA testing of patients with EGFR mutant non-small-cell lung cancer: droplet digital PCR versus next-generation sequencing compared with tissue-based results. JCO Precis Oncol. 2019; 3:1-9. [DOI:10.1200/PO.18.00401]
18. Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res. 2016; 22(23):5772-82. [DOI:10.1158/1078-0432.CCR-16-1231]
19. Kim Y, Shin S, Kim B, Lee K-A. Selecting short length nucleic acids localized in exosomes improves plasma EGFR mutation detection in NSCLC patients. Cancer Cell Int. 2019; 19:251. [DOI:10.1186/s12935-019-0978-8]
20. Karagur ER, Demiray A, Karagenc N, Elver E, Tokgun O, Yaren A, et al. Is there an advantage of monitoring via exosome-based detection of EGFR mutations during treatment in non-small cell lung cancer patients? Genetika. 2023; 55(1):83-93. [DOI:10.2298/GENSR2301083K]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |